Sutantatug envedotin
Antibody–drug conjugate
Also known as CRB-701
Evidence outlook · registrational
Cervical Cancer: registrational trial registered, not yet recruiting
No completed mid-stage readout is on record. Registrational readout expected around 2028-01-01.
Also in development:Urothelial Carcinoma · Phase 3
Company guidance: data expected Q1 2027 (Corbus Pharmaceuticals, 10 Nov 2026). “Anticipate reporting sutantatug envedotin plus Keytruda® combination data in first-line (1L) OPSCC in Q1 2027 to support potential further registration-enabling trials in the 1L setting.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT07230626 NCT07230626 · Cervical Cancer Registry: NCT07230626 | 3 | Overall Survival (Up to 3.5 years) 2028-01-01 | In progress: results expected 1 Jan 2028 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1/2 (2)
What this study did
What this study did
Competitive landscape
Other Nectin-4 drugs
Enfortumab Vedotin, Notiretatug rezetecan, Zelenectide pevedotin, IPH4502, LY4052031. Compare all 6 Nectin-4 drugs
5 other tracked programmes target this mechanism, 1 of them ahead of this one.
This drug's own stage for Cervical Cancer: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Sutantatug Envedotin: this drug | Phase 3 | Antibody–drug conjugate | Nectin-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Enfortumab Vedotin | Approved(overall) | Antibody–drug conjugate | Nectin-4 | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Jobevne (bevacizumab-Nwgd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Reliable signal | No reviewed efficacy summary in this indication | |
| Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex) | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Tisotumab Vedotin Humax-Tf-Adc (Tivdak) | Approved | Antibody–drug conjugate | Tissue Factor (TF) | Partial signal | NCT04697628: Overall Survival (From randomization to date of death due to any cause or censoring date, whichever occurred first (maximum up to 25 months)): Tisotumab Vedotin 11.5 Months (95% CI 9.8 to 14.9) | Chemotherapy 9.5 Months (95% CI 7.9 to 10.7) NCT03438396: Percentage of Participants With Confirmed Objective Response (OR) as Assessed by the Independent Review Committee (IRC) (From Day 1 through IRC verified disease progression, initiation of new anticancer therapy, study withdrawal, or death, whichever occurred first (approximately 20 months)): Tisotumab Vedotin 23.8 Percentage of Participants (95% CI 15.9 to 33.3) | |
| Vegzelma (bevacizumab-Adcd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Zirabev (bevacizumab-Bvzr) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Cadonilimab | Phase 3 | Multispecific antibody | PD-1×CTLA-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Enlonstobart | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Famitinib | Phase 3 | Small molecule | c-Kit, VEGFR2 (KDR), PDGFRbeta, VEGFR3, FLT1, FLT3 | not yet graded | No reviewed efficacy summary in this indication | |
| Notiretatug Rezetecan | Phase 3 | Antibody–drug conjugate | Nectin-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Sacituzumab Tirumotecan | Phase 3 | Antibody–drug conjugate | TROP2 | not yet graded | No reviewed efficacy summary in this indication | |
| Volrustomig | Phase 3 | Multispecific antibody | PD-1 x CTLA-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Camrelizumab | Phase 2/3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Balstilimab | Phase 2 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| ALE.P02 | Phase 1/2(overall) | Antibody–drug conjugate | Claudin-1 (CLDN1) | not yet graded | No reviewed efficacy summary in this indication | |
| GI-101A | Phase 1/2 | Protein / enzyme therapeutic | CTLA-4 / IL-2Rβγ | not yet graded | No reviewed efficacy summary in this indication | |
| IPH4502 | Phase 1(overall) | Antibody–drug conjugate | Nectin-4 | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Sutantatug envedotin to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.